Global Sickle Cell Anaemia Testing Market - 2024-2031
Global Sickle Cell Anemia Testing Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
To diagnose sickle cell disease, a sickle cell test looks for aberrant hemoglobin in the blood. Sickle cell anemia is characterized by the presence of these crescent or sickle-shaped red blood cells (RBCs), which are easily distinguishable from regular round RBCs.
The most common types of tests used to find sickle cell anemia include Hemoglobin S Solubility Test and Sodium Metabisulfite Test, Hemoglobinopathy (Hb) Evaluation, Genetic Testing (DNA analysis), DNA Sequencing and others.
Market
Dynamics: Drivers & Restraints
Increasing prevalence of sickle cell anemia disease worldwide
The increase in the prevalence of sickle cell anemia cases is expected to drive the market growth. Sickle cell tests evaluate the existence and relative quantity of hemoglobin S in a blood sample or discover abnormalities in the genes that make hemoglobin to assist in diagnosing sickle cell anemia and/or identify persons with the sickle cell characteristic.
For instance, according to the report by the CDC, sickle cell disease affects almost 100,000 Americans. 1 out of 365 African-Americans born with sickle cell disease each year. SCD occurs among about 1 out of every 16,300 Hispanic-American births. About 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).
Each year about 300,000 infants are born with major haemoglobin disorders including more than 2,00,000 cases of sickle-cell anemia in Africa. Thus, the increasing prevalence of the disease condition is expected to drive the market growth.
Restraint
High cost of the advanced testing
Next-generation sequencing (NGS) and DNA microarrays are examples of advanced testing techniques that are very accurate and insightful, but they are also very expensive. This may put people and healthcare organizations at a financial disadvantage, especially in environments with limited resources. Thus, high cost acts as a hindering factor of the market growth.
Segment AnalysisnThe global sickle cell anaemia testing market is segmented based on strip type, diabetes type, end-user, and region.
Kits segment accounted for 54.2% of the market share
Sickle cell anemia kits are designed for point-of-care testing, they can be used conveniently in clinics, hospitals, or even at home. No complex laboratory equipment is necessary, making them ideal for resource-limited settings or situations where quick results are needed.
The majority of kits yield results in a matter of minutes, facilitating prompt diagnosis and prompt beginning of treatment or referral for additional assessment. This can potentially avoid issues and speed up care. The increase in the launch of advanced kits that gives the results rapidly are expected to drive the segment growth.
For instance, in June 2023, Mylab Discovery Solutions introduced a novel, strip-based test named PathoCatch Sickle Cell Rapid Test for diagnosing Sickle Cell Anemia swiftly and accurately.
Geographical Analysis
North America is expected to hold a significant position in the global sickle cell anaemia testing market share
North America is expected to hold the dominant position in the market growth due to the increasing prevalence of the disease condition and the advancements in the products that are launched. The strong government support in research and developmental activities of the test solutions and kits is expected to drive market growth in the region.
The majority of US and Canadian states have screening programs in place to guarantee early detection. Testing is easier to get and more convenient due to new quick and point-of-care tests. Research, testing, and treatment program funding encourage market expansion. Thus, the above factors are expected to hold the market growth in the forecast period.
COVID-19 Impact AnalysisCOVID-19 has impacted the market growth significantly. The onset of the lockdown and has disrupted the supply chain analysis and the diagnosis and testing of the disease conditions have been reduced due to the unavailability of the test kits and also the diagnostic centers and the hospitals have been shut down for non-essential disease conditions.
Market Segmentation
By Test Type
• Hemoglobin S Solubility Test and Sodium Metabisulfite Test
• Hemoglobinopathy (Hb) Evaluation
• Genetic Testing (DNA analysis)
• DNA Sequencing
• Others
By Product Type
• Kits
• Reagents
By End-User
• Hospitals
• Diagnostic Centers
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa
Competitive LandscapeThe leading companies with a significant market share B. Braun Medical Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Terumo Europe NV, Becton and Dickinson Company, Zenroxmed Healthcare, Shenzhen Hawk Medical Instrument Co., Ltd (Hawkmed), Baxter, ICU Medical Inc., Micrel Medical Devices SA, and QuadMed, Inc among others.
Why Purchase the Report?• To visualize the global sickle cell anemia testing market segmentation based on test type, product type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of sickle cell anemia testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global sickle cell anemia testing market report would provide approximately 61 tables, 59 figures, and 180 Pages.
Target Audience 2023• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies